Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab (Avastin).

Literature DB >> 20037132

Bevacizumab (Avastin).

Abstract

Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.

Entities: Chemical

Mesh：

Substances：

Year: 2009 PMID： 20037132 PMCID： PMC7964163 DOI： 10.3174/ajnr.A1987

Source DB: PubMed Journal: AJNR Am J Neuroradiol ISSN： 0195-6108 Impact factor: 3.825

9 in total

1. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Authors: L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara
Journal: Cancer Res Date: 1997-10-15 Impact factor: 12.701

2. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.

Authors: F Yuan; Y Chen; M Dellian; N Safabakhsh; N Ferrara; R K Jain
Journal: Proc Natl Acad Sci U S A Date: 1996-12-10 Impact factor: 11.205

3. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.

Authors: P Borgström; K J Hillan; P Sriramarao; N Ferrara
Journal: Cancer Res Date: 1996-09-01 Impact factor: 12.701

Review 4. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors: Daniel J Hicklin; Lee M Ellis
Journal: J Clin Oncol Date: 2004-12-07 Impact factor: 44.544

5. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.

Authors: P Borgström; M A Bourdon; K J Hillan; P Sriramarao; N Ferrara
Journal: Prostate Date: 1998-04-01 Impact factor: 4.104

6. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

Authors: Hans-Peter Gerber; Napoleone Ferrara
Journal: Cancer Res Date: 2005-02-01 Impact factor: 12.701

Review 7. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors.

Authors: Debabrata Mukhopadhyay; Kaustubh Datta
Journal: Semin Cancer Biol Date: 2004-04 Impact factor: 15.707

8. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors: Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal: Nat Med Date: 2004-01-25 Impact factor: 53.440

Review 9. Vascular endothelial growth factor: basic science and clinical progress.

Authors: Napoleone Ferrara
Journal: Endocr Rev Date: 2004-08 Impact factor: 19.871

9 in total

29 in total

1. Characteristics of oral mucosal events related to bevacizumab treatment.

Authors: Igor T Gavrilovic; Yevgeniy Balagula; Alyx C Rosen; Vijay Ramaswamy; Maura N Dickler; Ira J Dunkel; Mario E Lacouture
Journal: Oncologist Date: 2012-01-26

2. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.

Authors: Ola Abbas; Ali Shamseddin; Sally Temraz; Ali Haydar
Journal: BMJ Case Rep Date: 2013-02-21

Review 3. Commonalities Between COVID-19 and Radiation Injury.

Authors: Carmen I Rios; David R Cassatt; Brynn A Hollingsworth; Merriline M Satyamitra; Yeabsera S Tadesse; Lanyn P Taliaferro; Thomas A Winters; Andrea L DiCarlo
Journal: Radiat Res Date: 2021-01-01 Impact factor: 2.841

4. Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH.

Authors: Divyabharathy Tsiros; Casey E Sheehy; Surenna Pecchia; Matthew A Nugent
Journal: J Biol Chem Date: 2019-10-10 Impact factor: 5.157

5. Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy.

Authors: R Singh; K Kesavabhotla; S A Kishore; Z Zhou; A J Tsiouris; C G Filippi; J A Boockvar; I Kovanlikaya
Journal: AJNR Am J Neuroradiol Date: 2016-05-26 Impact factor: 3.825

6. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors: C Rohrmeier; H G Sachs; T S Kuehnel
Journal: Eur Arch Otorhinolaryngol Date: 2011-07-31 Impact factor: 2.503

7. [Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring].

Authors: N Schramm; M Schlemmer; C Rist; R Issels; M F Reiser; F Berger
Journal: Radiologe Date: 2010-04 Impact factor: 0.635

Review 8. Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Authors: Bruce C Baguley; Dietmar W Siemann
Journal: Expert Opin Investig Drugs Date: 2010-11 Impact factor: 6.206

9. A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis.

Authors: Ting Liu; Changzheng Shi; Linqi Duan; Zehang Zhang; Liangping Luo; Shreya Goel; Weibo Cai; Tianfeng Chen
Journal: J Mater Chem B Date: 2018-06-29 Impact factor: 6.331

10. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.

Authors: A Hilario; J M Sepulveda; A Hernandez-Lain; E Salvador; L Koren; R Manneh; Y Ruano; A Perez-Nuñez; A Lagares; A Ramos
Journal: Clin Transl Oncol Date: 2016-03-30 Impact factor: 3.405